Gene Transplant Market Report 2025

The gene transplant market size has grown rapidly in recent years. It will grow from $3.65 billion in 2024 to $4.13 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth in the historic period can be linked to rising success rates in early clinical trials, greater adoption of next-generation sequencing (NGS), increased development of cell-based therapies, and wider availability of orphan drug designations.

The gene transplant market size is expected to see rapid growth in the next few years. It will grow to $6.72 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be linked to heightened focus on one-time curative treatments, expansion of manufacturing capacity for gene therapies, growing regulatory harmonization, increasing applications in neurological disorders, and greater use of synthetic biology platforms. Key trends during the forecast period include integration of artificial intelligence with gene editing platforms, combination of gene therapy with regenerative medicine, use of wearable biosensors in gene therapy trials, application of 3D bioprinting with gene-modified cells, and incorporation of blockchain in clinical data management.

The growth of gene therapy is expected to drive the expansion of the gene transplant market in the coming years. Gene therapy is a technique that alters a person's genes to prevent or treat diseases. This field is growing due to advancements in delivery systems, which allow for the safe, efficient, and targeted transport of genetic material into cells. Gene therapy plays a key role in managing genetic disorders by offering targeted treatments that can correct or replace defective genes, providing solutions for conditions that were once untreatable. By addressing the root cause of diseases, gene therapy helps reduce symptoms and halt disease progression, ultimately improving patient outcomes and quality of life. For example, the American Society of Gene & Cell Therapy (ASGCT) reported in December 2024 that the FDA approved six gene therapy products in 2023, an increase from five approvals in 2022. As a result, the rise in gene therapy is accelerating the growth of the gene transplant market.

Key players in the gene transplant market are focusing on the development of advanced technologies, such as automated cloning platforms, to enhance the efficiency, precision, and speed of gene therapy. Automated cloning platforms are systems that isolate and culture single cells into monoclonal lines, improving the speed, consistency, and accuracy of gene transplant and therapy procedures. For instance, in November 2024, iotaSciences Ltd., a UK-based life sciences technology company, launched the XT Single-Cell Cloning Platform. This platform integrates automated microfluidics, AI-driven image analysis, and nano-dispensing technology, enabling high-throughput and precise isolation of individual cells. Designed to accelerate gene therapy development, it ensures monoclonality - a key regulatory requirement - while reducing processing time from weeks to days. This system also supports CRISPR-based gene editing by efficiently delivering editing components to target cells, thus advancing the development of next-generation therapies.

In January 2025, Roche, a Swiss pharmaceutical company, expanded its capabilities by acquiring Poseida Therapeutics Inc. for $1.5 billion. This acquisition strengthens Roche’s gene transplant and cell therapy portfolio by giving it access to Poseida’s non-viral gene editing and delivery technologies, which are designed to treat genetic disorders and cancers. Poseida Therapeutics Inc. is a US-based company focused on developing gene transplant therapies.

Major players in the gene transplant market are Bayer AG, Novartis AG, CSL Behring LLC, Charles River Laboratories International Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., Rocket Pharmaceuticals Inc., Voyager Therapeutics Inc., Sangamo Therapeutics Inc., Editas Medicine Inc., Krystal Biotech Inc., bluebird bio Inc., Orchard Therapeutics plc, 4D Molecular Therapeutics Inc., Solid Biosciences Inc., uniQure N.V., and MeiraGTx Holdings plc.

North America was the largest region in the gene transplant market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gene transplant report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gene transplant market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Gene transplant refers to the process of introducing healthy or modified genes into a patient’s cells to replace or repair defective genes responsible for disease. Its primary goal is to correct genetic disorders, restore normal cellular function, or provide therapeutic effects, such as enhancing the immune system’s ability to target diseases.

The primary types of gene transplant are autologous and allogeneic. Autologous involves collecting a patient’s own cells, genetically modifying them, and transplanting them back into the same individual to treat or prevent disease. Applications include genetic disorders, cancer, rare diseases, and more, serving hospitals, research institutions, biotechnology companies, and other end users.

The gene transplant market research report is one of a series of new reports that provides gene transplant market statistics, including the gene transplant industry global market size, regional shares, competitors with the gene transplant market share, detailed gene transplant market segments, market trends, and opportunities, and any further data you may need to thrive in the gene transplant industry. This gene transplant market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gene transplant market includes revenues earned by entities through gene therapy consultation, genetic engineering, cell processing and modification, vector delivery services, clinical trial support, and patient-specific treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.